{"url":"https://lda.gov/api/v1/filings/502870c0-d272-474e-8980-b4e5519180f8/","filing_uuid":"502870c0-d272-474e-8980-b4e5519180f8","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/502870c0-d272-474e-8980-b4e5519180f8/print/","filing_document_content_type":"text/html","income":null,"expenses":"2360000.00","expenses_method":"C","expenses_method_display":"C","posted_by_name":"Aiken Hackett","dt_posted":"2026-07-20T20:22:29-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1201 New York Avenue NW","registrant_address_2":"Suite 1300","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":6245,"url":"https://lda.gov/api/v1/registrants/6245/","house_registrant_id":32505,"name":"BIOTECHNOLOGY INNOVATION ORGANIZATION","description":"Trade Association","address_1":"1201 New York Avenue NW","address_2":"Suite 1300","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"AIKEN HACKETT","contact_telephone":"+1 202-962-9200","dt_updated":"2026-07-30T15:18:39.397367-04:00"},"client":{"id":107792,"url":"https://lda.gov/api/v1/clients/107792/","client_id":12,"name":"BIOTECHNOLOGY INNOVATION ORGANIZATION","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2016-01-01"},"lobbying_activities":[{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"CFIUS and Foreign Investment ---Outbound Investment Security Program Drug Importation Drug Pricing ---CMMI: GLOBE and GUARD Models ---International Pricing Policies ---Most Favored Nation Drug Pricing Proposals ---Reference Pricing in Drug Reimbursement ---Tariffs Foreign Drug Data Protection Laws ---A bill to prohibit contracting with certain biotechnology providers, and for other purposes. ---Implementation of BIOSECURE Act ---Implementation of COINS Global Supply Chain Resiliency Incentives for Domestic Manufacturing Intellectual Property International Enforcement ---China Synthetic Biotech Tariffs Trade Relations ---Section 232 US-China Trade Relations ---H.R.9102: BINSA Act ---Implementation of COINS ---IP Provisions World Health Organization (WHO) ---WHO Pandemic Preparedness Accord","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":66411,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"LACHMANN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151198,"prefix":"ms","prefix_display":"MS.","first_name":"AIKEN","nickname":null,"middle_name":null,"last_name":"HACKETT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138511,"prefix":null,"prefix_display":null,"first_name":"AMBER","nickname":null,"middle_name":null,"last_name":"MANKO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138347,"prefix":null,"prefix_display":null,"first_name":"ELISABETH","nickname":null,"middle_name":null,"last_name":"FOX","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":112560,"prefix":null,"prefix_display":null,"first_name":"KRISTIN","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149760,"prefix":null,"prefix_display":null,"first_name":"CHRIS","nickname":null,"middle_name":null,"last_name":"JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154653,"prefix":null,"prefix_display":null,"first_name":"JONATHAN","nickname":null,"middle_name":null,"last_name":"DANIELS","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":16,"name":"Natl Security Council (NSC)"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"FY 2026 Appropriations for Agencies ---Administration for Strategic Preparedness and Response (ASPR) ---Biomedical Advanced Research and Development Authority (BARDA) ---Centers for Disease Control and Prevention (CDC) ---Centers for Medicare and Medicaid Services (CMS) ---Food & Drug Administration (FDA) ---Health Resources and Services Administration (HRSA) ---National Institutes of Health (NIH) FY 2026 Appropriations for Specific Issues ---Antimicrobial Resistance (General) ---Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement ---Clinical Trial Data From China ---CMMI Models: GLOBE and GUARD ---Funding for Section 317 ---Funding for Strategic National Stockpile ---OMB Federal Research Proposed Rule ---Pandemic Preparedness ---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA) ---Vaccine Access & Compensation","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151039,"prefix":"ms","prefix_display":"MS.","first_name":"BAILEY","nickname":null,"middle_name":"LAUREN","last_name":"MCCUE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152670,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"ACKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":137893,"prefix":"ms","prefix_display":"MS.","first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"WHEELER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138347,"prefix":null,"prefix_display":null,"first_name":"ELISABETH","nickname":null,"middle_name":null,"last_name":"FOX","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":50504,"prefix":null,"prefix_display":null,"first_name":"PHYLLIS","nickname":null,"middle_name":null,"last_name":"ARTHUR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151198,"prefix":"ms","prefix_display":"MS.","first_name":"AIKEN","nickname":null,"middle_name":null,"last_name":"HACKETT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146903,"prefix":null,"prefix_display":null,"first_name":"PRANEEL","nickname":null,"middle_name":null,"last_name":"JADAV","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149760,"prefix":null,"prefix_display":null,"first_name":"CHRIS","nickname":null,"middle_name":null,"last_name":"JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138511,"prefix":null,"prefix_display":null,"first_name":"AMBER","nickname":null,"middle_name":null,"last_name":"MANKO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":112560,"prefix":null,"prefix_display":null,"first_name":"KRISTIN","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"Antitrust Legislation ---Oversight Pharmacy Benefit Managers Artificial Intelligence (AI) Bayh-Dole Act/Tech Transfer ---Bayh-Dole Act ---March-In Rights Compulsory Licensing ---28 U.S.C. 1498 - Patent and copyright cases Data Privacy ---H.R.8413: SECURE Data Act ---Implementation of BIOSECURE Act Drug Patenting ---H.R.3160/S.1553: PREVAIL Act ---H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act ---H.R.9142: Prohibiting Adversarial Patents Act of 2026 ---S.43/H.R.6485: Skinny Labels, Big Savings Act ---S.527: Prescription Pricing for the People Act ---S.1041: Affordable Prescriptions for Patients Act ---S.1095: Stop STALLING Act ---S.1096: Preserve Access to Affordable Generics and Biosimilars Act ---S.1097: Interagency Patent Coordination and Improvement Act of 2025 ---S.1546/H.R.3152: Patent Eligibility Restoration Act (PERA) ---S.2658: Medication Affordability and Patient Integrity Act ---S.3014: Ensuring Timely Access to Generics Act of 2025 ---Department of Commerce Patent Valuation Fee Proposal ---Patent Litigation Reform ---Patent Tax/fees ---PTAB Reform ---Restrictions on Intellectual Property Rights ---Section 101 Modernization Foreign Drug Data Protection Law ---Implementation of BIOSECURE Act Intellectual Property Enforcement ---China","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":66411,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"LACHMANN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151198,"prefix":"ms","prefix_display":"MS.","first_name":"AIKEN","nickname":null,"middle_name":null,"last_name":"HACKETT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":112560,"prefix":null,"prefix_display":null,"first_name":"KRISTIN","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149760,"prefix":null,"prefix_display":null,"first_name":"CHRIS","nickname":null,"middle_name":null,"last_name":"JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138511,"prefix":null,"prefix_display":null,"first_name":"AMBER","nickname":null,"middle_name":null,"last_name":"MANKO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138347,"prefix":null,"prefix_display":null,"first_name":"ELISABETH","nickname":null,"middle_name":null,"last_name":"FOX","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"FY 2026 Appropriations for Agencies ---Administration for Strategic Preparedness and Response (ASPR) ---Centers for Disease Control and Prevention (CDC) ---Centers for Medicare and Medicaid (CMS) ---Food & Drug Administration (FDA) ---Health Resources and Services Administration (HRSA) ---HHS Office of Infectious Disease and HIV/AIDS Policy ---National Institutes of Health (NIH) FY 2026 Appropriations for Specific Issues ---Alternative Funding Programs ---Antimicrobial Resistance (General) ---Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement ---CICP ---CMMI: GLOBE and GUARD Models ---Drug Pricing ---Funding for Strategic National Stockpile ---Funding for Women's Health Research ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Influenza Planning & Response ---MCM PRV Reauthorization ---Pandemic Preparedness -R&D Funding for Medical Countermeasures ---Pediatric Priority Review Voucher ---Prescription Drug User Fee Act (PDUFA) VIII Implementation ---Project Bioshield ---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA) ---Section 317 Immunization Program ---Vaccines and Infectious Diseases ---Vaccine Injury Compensation Program 340B Drug Discount Program ---H.R.5256: 340B ACCESS Act ---H.R.9504: Tax Exempt Hospital Transparency Act ---Program Implementation & Oversight ---Rebate Models ---SECURE 340B Act ---SUSTAIN 340B Act Accelerated Approval Artificial Intelligence (AI) Alternative Funding Programs Biodefense Research, Development and Procurement Issues (Non-Funding) ---Gain of function (Viral Gain of Function Research Moratorium Act, SAFE Risky Research Act) ---Implementation of BIOSECURE Act ---MCM PRV Program Reauthorization ---National Defense Authorization Act 2027 ---Reasonable Pricing Clauses in BARDA Contracts ---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA) ---Risky Research Review Act ---VICP Loopholes Biosimilars ---S.1414: Expedited Access to Biosimilars Act ---Biosimilars Competition (General) ---Biosimilar Red Tape Elimination Act ---Interchangeability and Pharmacy Substitution Cell & Gene Therapy ---H.R.1672: Maintaining Investments and New Innovation (MINI) Act Clinical Trial Data in China ---Next-Generation U.S. Clinical Development to Accelerate Cures - Legislative Discussion Draft Data Privacy ---H.R.8413: SECURE Data Act ---Clinical Trial Data in China ---Implementation of BIOSECURE Act Diversity & Inclusion ---H.R.3521: Clinical Trial Modernization Act ---Decentralized Clinical Trials Drug Evaluation and Review ---FDA Hiring Flexibility Drug Importation Drug Manufacturing, Quality & Distribution ---S.3788: CLEAR Labels Act ---Advanced Manufacturing ---Compounding Pharmacies ---Drug Shortages ---Supply Chain Integrity and Traceability Drug Patenting ---H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act ---H.R.6485/S.43: Skinny Labels, Big Savings Act ---S.527: Prescription Pricing for the People Act ---S.1041: Affordable Prescriptions for Patients Act ---S.1095: Stop STALLING Act ---S.1096: Preserve Access to Affordable Generics and Biosimilars Act ---S.1097: Interagency Patent Coordination and Improvement Act ---S.2658: Medication Affordability and Patient Integrity Act Drug Pricing ---H.R.1672: Maintaining Investments and New Innovation (MINI) Act ---H.R.5391/S.2764 Protecting Patient Access to Cancer and Complex Therapies Act ---S.526: Pharmacy Benefit Manager Transparency Act ---S.527: Prescription Pricing for the People Act ---S.832: Ensuring Pathways to Innovative Cures (EPIC) Act ---S.1095: Stop STALLING Act ---S.1096: Preserve Access to Affordable Generics and Biosimilars Act ---S.1302: Increasing Transparency in Generic Drug Application ---Access to Innovative Treatments Act ---Biosimilar Red Tape Elimination Act ---CMMI: GLOBE and GUARD Models ---CMMI Authority ---DRUG Act ---Ensuring Access to Generic Medications Act ---Ensuring Timely Access to Generics ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Implementation of ORPHAN Cures Act ---International Pricing Policies ---Medicare Drug Price Negotiation Act ---Modernizing and Ensuring PBM Accountability (MEPA) Act ---National Coverage Determination ---Most Favored Nation Drug Pricing Proposals ---Patient Cost-Sharing and Implementation ---Senate Finance Committee Minority RFI on Drug Pricing ---Tariffs Efforts to Expand the Bio Economy & Bio Manufacturing Foreign Drug Data Protection Law ---Implementation of BIOSECURE Act Generic Drug Entry ---H.R.6485/S.43: Skinny Labels, Big Savings Act ---S.1095: Stop STALLING Act ---Generic Drug Application Review Reforms Issues Relating to Medical Research and Animal Testing ---FDA Modernization Act 3.0 Medicaid ---Alternative Payment Arrangements for Gene Therapies ---CMMI (GENEROUS Model) ---CMMI: GLOBE and GUARD Models ---Drug Benefit Design ---International Pricing Policies ---Medicaid VBPs for Patients (MVP) Act ---Most Favored Nation Drug Pricing Proposals ---Pricing and Rebates National Defense ---Medical Countermeasure Priority Review Voucher Reauthorization ---National Defense Authorization Act of 2027 National Security ---S.3741: Biosecurity Modernization and Innovation Act of 2026 ---Clinical Trial Data in China ---CMMI: GLOBE and GUARD Models ---Implementation of BIOSECURE Act ---International Pricing Policies ---Medical Countermeasure Priority Review Voucher Reauthorization ---NSC/OSTP priorities ---Nucleic acid synthesis security and biotechnology governance ---Most Favored Nation Drug Pricing Proposals Opioid Crisis ---Non-Opioid Analgesics Orphan Drug Issues ---S.705: Innovation in Pediatric Drugs Act of 2025 ---Implementation of ORPHAN Cures Act ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Orphan Drug Tax Credit ---Retaining Access and Restoring Exclusivity (RARE) Act Pandemic Preparedness ---Drug Supply Chain Management ---R&D Funding for Medical Countermeasures ---Supply Chain Issues ---WHO Pandemic Preparedness Accord Precision Medicine Initiative Rare Pediatric Disease Priority Review ---S.822: Scientific EXPERT Act ---Rare Disease Pilot Program Reimbursement and Coverage of Innovative Products ---S.864/H.R.6423: HELP Copays Act ---S.1816: Improving Seniors Timely Access to Care Act of 2025 ---Access to Innovative Treatments ---Administrative Rebate Rule ---CMMI Authority ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Medicaid VBPs for Patients (MVP) Act ---Medicare Drug Price Negotiation Act ---Medicare Part B Physician-Administered Products ---National Coverage Determination ---Patient Cost-Sharing and Smoothing ---Prescription Drug Price Relief Act ---Prior Authorization Reform ---SAFE STEP Act ---Step Therapy Vaccines and Infectious Diseases ---Adult Immunization ---Maternal Immunization ---MCM Manufacturing & Capacity ---MCM R&D Incentives ---PASTEUR ACT ---SAFE STEP Act ---Vaccine and Antimicrobial Resistance Product Development and Incentives ---Vaccine Injury Compensation Modernization Act ---Vaccine Injury Compensation Program ---Vaccine Safety ---Vaccine Safety Net and Vaccine Infrastructure ---Value of Vaccines and Vaccine Confidence","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151198,"prefix":"ms","prefix_display":"MS.","first_name":"AIKEN","nickname":null,"middle_name":null,"last_name":"HACKETT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":50504,"prefix":null,"prefix_display":null,"first_name":"PHYLLIS","nickname":null,"middle_name":null,"last_name":"ARTHUR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":112560,"prefix":null,"prefix_display":null,"first_name":"KRISTIN","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66411,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"LACHMANN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":137893,"prefix":"ms","prefix_display":"MS.","first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"WHEELER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138511,"prefix":null,"prefix_display":null,"first_name":"AMBER","nickname":null,"middle_name":null,"last_name":"MANKO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138347,"prefix":null,"prefix_display":null,"first_name":"ELISABETH","nickname":null,"middle_name":null,"last_name":"FOX","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146903,"prefix":null,"prefix_display":null,"first_name":"PRANEEL","nickname":null,"middle_name":null,"last_name":"JADAV","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149760,"prefix":null,"prefix_display":null,"first_name":"CHRIS","nickname":null,"middle_name":null,"last_name":"JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151039,"prefix":"ms","prefix_display":"MS.","first_name":"BAILEY","nickname":null,"middle_name":"LAUREN","last_name":"MCCUE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152670,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"ACKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":64,"name":"Federal Trade Commission (FTC)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":16,"name":"Natl Security Council (NSC)"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"HOM","general_issue_code_display":"Homeland Security","description":"FY 2026 Appropriations for Agencies ---Centers for Disease Control and Prevention Vaccine Programs ---Health Resources and Services Administration (HRSA) ---HHS Office of Infectious Disease and HIV/AIDS Policy FY 2026 Appropriations for Specific Issues ---Antimicrobial Resistance (General) ---Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement ---Funding for Strategic National Stockpile ---Medical Countermeasure Priority Review Voucher Reauthorization ---Pandemic Preparedness -R&D Funding for Medical Countermeasures ---VICP/CICP Biodefense Research, Development and Procurement Issues ---Ebola BDBV Outbreak ---Gene Editing ---Hanta Virus ---Medical Countermeasure Priority Review Voucher Reauthorization ---National Defense Authorization Act 2027 ---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA) ---Risky Research Review Act ---WHO Pandemic Preparedness Accord Pandemic Preparedness ---Medical Countermeasure Priority Review Voucher Reauthorization ---Reauthorization of PAHPA ---Supply Chain Issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151198,"prefix":"ms","prefix_display":"MS.","first_name":"AIKEN","nickname":null,"middle_name":null,"last_name":"HACKETT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138511,"prefix":null,"prefix_display":null,"first_name":"AMBER","nickname":null,"middle_name":null,"last_name":"MANKO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":112560,"prefix":null,"prefix_display":null,"first_name":"KRISTIN","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146903,"prefix":null,"prefix_display":null,"first_name":"PRANEEL","nickname":null,"middle_name":null,"last_name":"JADAV","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":137893,"prefix":"ms","prefix_display":"MS.","first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"WHEELER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152670,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"ACKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":50504,"prefix":null,"prefix_display":null,"first_name":"PHYLLIS","nickname":null,"middle_name":null,"last_name":"ARTHUR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149760,"prefix":null,"prefix_display":null,"first_name":"CHRIS","nickname":null,"middle_name":null,"last_name":"JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154653,"prefix":null,"prefix_display":null,"first_name":"JONATHAN","nickname":null,"middle_name":null,"last_name":"DANIELS","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"FY 2026 Appropriations for Agencies ---Administration for Strategic Preparedness and Response (ASPR) ---Biomedical Advanced Research and Development Authority (BARDA) ---Centers for Disease Control and Prevention (CDC) ---Food & Drug Administration (FDA) ---Health Resources and Services Administration (HRSA) ---HHS Office of Infectious Disease and HIV/AIDS Policy ---National Institutes of Health (NIH) FY 2026 Appropriations for Specific Issues ---Antimicrobial Resistance (General) ---Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement ---Funding for Medical Countermeasures ---Funding for Section 317 ---Funding for Strategic National Stockpile ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---MCM PRV Reauthorization ---Pandemic Flu ---Pandemic Preparedness - R&D Funding for Medical Countermeasures ---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA) ---VICP/CICP Antimicrobial Resistance Biodefense Research, Development and Procurement Issues ---Gene Editing ---HHS Reorganization ---Medical Countermeasure Priority Review Voucher Reauthorization CDC Reform Pandemic Preparedness ---Medical Countermeasure Priority Review Voucher Reauthorization ---R&D Funding for Medical Countermeasures","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":137893,"prefix":"ms","prefix_display":"MS.","first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"WHEELER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":112560,"prefix":null,"prefix_display":null,"first_name":"KRISTIN","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151198,"prefix":"ms","prefix_display":"MS.","first_name":"AIKEN","nickname":null,"middle_name":null,"last_name":"HACKETT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138511,"prefix":null,"prefix_display":null,"first_name":"AMBER","nickname":null,"middle_name":null,"last_name":"MANKO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138347,"prefix":null,"prefix_display":null,"first_name":"ELISABETH","nickname":null,"middle_name":null,"last_name":"FOX","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149760,"prefix":null,"prefix_display":null,"first_name":"CHRIS","nickname":null,"middle_name":null,"last_name":"JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151039,"prefix":"ms","prefix_display":"MS.","first_name":"BAILEY","nickname":null,"middle_name":"LAUREN","last_name":"MCCUE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":50504,"prefix":null,"prefix_display":null,"first_name":"PHYLLIS","nickname":null,"middle_name":null,"last_name":"ARTHUR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146903,"prefix":null,"prefix_display":null,"first_name":"PRANEEL","nickname":null,"middle_name":null,"last_name":"JADAV","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152670,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"ACKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":64,"name":"Federal Trade Commission (FTC)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"FY 2026 Appropriations for Specific Issues ---Alternative Funding Programs ---Antimicrobial Resistance (General) ---CMMI: GLOBE and GUARD Models ---Drug Pricing ---Pandemic Preparedness - R&D Funding for Medical Countermeasures ---Vaccines and Infectious Diseases 340B Drug Discount Program ---H.R.5256: 340B ACCESS Act ---H.R.9504: Tax Exempt Hospital Transparency Act ---Program Implementation & Oversight ---PROTECT 340B Act ---Rebate Models ---SECURE 340B Act ---SUSTAIN 340B Act Alternative Funding Programs Biosimilars ---Biosimilars Red Tape Elimination Act ---Interchangeability and Pharmacy Substitution Cell & Gene Therapy ---H.R.1672: Maintaining Investments and New Innovation (MINI) Act Clinical Trial Data in China Data Privacy ---H.R.8413: SECURE Data Act Drug Manufacturing, Quality & Distribution ---Advanced Manufacturing ---Compounded Medicines ---Drug Shortages ---Supply Chain Integrity and Traceability Drug Patenting ---S.43/H.R.6485: Skinny Labels, Big Savings Act ---S.527: Prescription Pricing for the People Act ---S.1095: Stop STALLING Act ---S.1096: Preserve Access to Affordable Generics and Biosimilars Act ---S.1097: Interagency Patent Coordination and Improvement Act ---Patent Thickets ---Restrictions on Intellectual Property Rights Drug Pricing ---H.R.1492: Ensuring Pathways to Innovative Cures (EPIC) Act ---H.R.1672: Maintaining Investments and New Innovation (MINI) Act ---H.R.5391/S.2764: Protecting Patient Access to Cancer and Complex Therapies Act ---S.526: Pharmacy Benefit Manager Transparency Act ---S.1096: Preserve Access to Affordable Generics and Biosimilars Act ---CMMI: GLOBE and GUARD Models ---CMMI Authority ---Implementation of ORPHAN Cures Act ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Most Favored Nation Drug Pricing Proposals ---Patient Cost-Sharing and Implementation ---PBM Reform ---Strengthening Innovation in Medicare and Medicaid Act Foreign Drug Data Protection Laws Medicaid ---S.526: Pharmacy Benefit Manager Transparency Act ---Alternative Payment Arrangements for Gene Therapies ---CMMI (GENEROUS Model) ---CMMI: GLOBE and GUARD Models ---Drug Benefit Design ---Medicaid Drug Rebate Program ---Most Favored Nation in Medicaid ---Pricing and Rebates ---Value-Based Purchasing (VBP) Rule National Defense ---National Defense Authorization Act of 2027 Opioid Crisis ---Non-Opioid Analgesics Orphan Drug Issues ---Implementation of ORPHAN Cures Act ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Pediatric Priority Review Voucher Program Reauthorization Precision Medicine Initiative Reimbursement and Coverage of Innovative Products ---S.864/H.R.6423: HELP Copays Act ---CMMI Authority Vaccines and Infectious Diseases ---Adult Immunization ---Countermeasures Injury Compensation Program ---MCM Manufacturing & Capacity ---Medical Countermeasure Priority Review Voucher Reauthorization ---Vaccine Injury Compensation Program ---Vaccine Safety and Quality ---Value of Vaccines and Vaccine Confidence","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151198,"prefix":"ms","prefix_display":"MS.","first_name":"AIKEN","nickname":null,"middle_name":null,"last_name":"HACKETT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":112560,"prefix":null,"prefix_display":null,"first_name":"KRISTIN","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138511,"prefix":null,"prefix_display":null,"first_name":"AMBER","nickname":null,"middle_name":null,"last_name":"MANKO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":137893,"prefix":"ms","prefix_display":"MS.","first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"WHEELER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138347,"prefix":null,"prefix_display":null,"first_name":"ELISABETH","nickname":null,"middle_name":null,"last_name":"FOX","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149760,"prefix":null,"prefix_display":null,"first_name":"CHRIS","nickname":null,"middle_name":null,"last_name":"JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151039,"prefix":"ms","prefix_display":"MS.","first_name":"BAILEY","nickname":null,"middle_name":"LAUREN","last_name":"MCCUE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152670,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"ACKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66411,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"LACHMANN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154653,"prefix":null,"prefix_display":null,"first_name":"JONATHAN","nickname":null,"middle_name":null,"last_name":"DANIELS","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"SMB","general_issue_code_display":"Small Business","description":"Banking Policy Impacting Emerging Companies ---Regulatory Burden Capital Formation Incentives ---H.R.3323: Helping Startups Continue To Grow Act ---H.R.3339: Equal Opportunity for All Investors Act of 2025 ---H.R.3348: Accredited Investor Definition Review Act ---H.R.3382/S.2924: Small Entity Update Act ---H.R.3394: Fair Investment Opportunities for Professional Experts Act ---H.R.4430: Expanding WKSI Eligibility Act Capital Market Enhancements ---Accredited Investor Definition ---Public Float Threshold Update ---Small Business Capital Formation Enhancement Act Mergers and Acquisitions Small Business Innovation Research (SBIR) Program ---H.R.3169/S.1573: SBIR/STTR Reauthorization Act of 2025 ---H.R.4777: INNOVATE Act ---H.R.5100: To extend the SBIR and STTR programs, and for other purposes. ---S.3971: Small Business Innovation and Economic Security Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138511,"prefix":null,"prefix_display":null,"first_name":"AMBER","nickname":null,"middle_name":null,"last_name":"MANKO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66411,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"LACHMANN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151198,"prefix":"ms","prefix_display":"MS.","first_name":"AIKEN","nickname":null,"middle_name":null,"last_name":"HACKETT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149760,"prefix":null,"prefix_display":null,"first_name":"CHRIS","nickname":null,"middle_name":null,"last_name":"JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":112560,"prefix":null,"prefix_display":null,"first_name":"KRISTIN","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138347,"prefix":null,"prefix_display":null,"first_name":"ELISABETH","nickname":null,"middle_name":null,"last_name":"FOX","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"FY 2026 Appropriations for Specific Issues ---Vaccines and Infectious Diseases ---VICP/CICP Capital Formation Incentives ---Net Operating Loss Advance Refunds Orphan Drug Issues ---Implementation of ORPHAN Cures Act Pandemic Preparedness Research & Development Tax Credit Reforms ---H.R.1: One Big Beautiful Bill Act ---American Innovation and R&D Competitiveness Act ---Expensing of R&D Expenditures ---Tax Relief for American Families and Workers Act Vaccines and Infectious Disease ---Countermeasure Injury Compensation Fund Amendment Act ---Vaccine Injury Compensation Modernization Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151198,"prefix":"ms","prefix_display":"MS.","first_name":"AIKEN","nickname":null,"middle_name":null,"last_name":"HACKETT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138511,"prefix":null,"prefix_display":null,"first_name":"AMBER","nickname":null,"middle_name":null,"last_name":"MANKO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149760,"prefix":null,"prefix_display":null,"first_name":"CHRIS","nickname":null,"middle_name":null,"last_name":"JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":137893,"prefix":"ms","prefix_display":"MS.","first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"WHEELER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":50504,"prefix":null,"prefix_display":null,"first_name":"PHYLLIS","nickname":null,"middle_name":null,"last_name":"ARTHUR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151039,"prefix":"ms","prefix_display":"MS.","first_name":"BAILEY","nickname":null,"middle_name":"LAUREN","last_name":"MCCUE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":112560,"prefix":null,"prefix_display":null,"first_name":"KRISTIN","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152670,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"ACKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138347,"prefix":null,"prefix_display":null,"first_name":"ELISABETH","nickname":null,"middle_name":null,"last_name":"FOX","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}